vs
Side-by-side financial comparison of Ralliant Corp (RAL) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $529.1M, roughly 1.2× Ralliant Corp). Royalty Pharma plc runs the higher net margin — 34.4% vs 7.5%, a 26.9% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -0.5%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
RAL vs RPRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $529.1M | $622.0M |
| Net Profit | $39.9M | $214.2M |
| Gross Margin | 50.8% | — |
| Operating Margin | 9.8% | 62.4% |
| Net Margin | 7.5% | 34.4% |
| Revenue YoY | -0.5% | 4.8% |
| Net Profit YoY | -56.1% | 2.9% |
| EPS (diluted) | $0.35 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0M | ||
| Q3 25 | $529.1M | $609.3M | ||
| Q2 25 | $503.3M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | — | $593.6M | ||
| Q3 24 | $531.7M | $564.7M | ||
| Q2 24 | $533.7M | $537.3M | ||
| Q1 24 | — | $568.0M |
| Q4 25 | — | $214.2M | ||
| Q3 25 | $39.9M | $288.2M | ||
| Q2 25 | $47.6M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $90.9M | $544.0M | ||
| Q2 24 | $64.8M | $102.0M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | — | — | ||
| Q3 25 | 50.8% | — | ||
| Q2 25 | 49.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 51.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 62.4% | ||
| Q3 25 | 9.8% | 70.1% | ||
| Q2 25 | 11.7% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | 20.9% | — | ||
| Q2 24 | 19.7% | 50.2% | ||
| Q1 24 | — | -13.0% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | 7.5% | 47.3% | ||
| Q2 25 | 9.5% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 17.1% | 96.3% | ||
| Q2 24 | 12.1% | 19.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.35 | $0.67 | ||
| Q2 25 | $0.42 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $0.81 | $1.21 | ||
| Q2 24 | $0.57 | $0.23 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.2M | $618.7M |
| Total DebtLower is stronger | $1.1B | $9.0B |
| Stockholders' EquityBook value | $3.0B | $9.7B |
| Total Assets | $5.3B | $19.6B |
| Debt / EquityLower = less leverage | 0.39× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | $264.2M | $938.9M | ||
| Q2 25 | $198.6M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $1.1B | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | — | $9.7B | ||
| Q3 25 | $3.0B | $9.6B | ||
| Q2 25 | $3.0B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | $4.0B | $10.3B | ||
| Q2 24 | $4.0B | $9.8B | ||
| Q1 24 | — | $9.9B |
| Q4 25 | — | $19.6B | ||
| Q3 25 | $5.3B | $19.3B | ||
| Q2 25 | $5.2B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $18.2B | ||
| Q3 24 | — | $18.0B | ||
| Q2 24 | — | $17.7B | ||
| Q1 24 | — | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.39× | 0.93× | ||
| Q2 25 | 0.38× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $138.6M | $827.1M |
| Free Cash FlowOCF − Capex | $126.6M | — |
| FCF MarginFCF / Revenue | 23.9% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | 3.47× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $827.1M | ||
| Q3 25 | $138.6M | $702.6M | ||
| Q2 25 | — | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | — | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | — | $664.6M |
| Q4 25 | — | — | ||
| Q3 25 | $126.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 23.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | 3.47× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
